🔥 March 2024: Shaping the Future with Peptide Innovations 🔥
March 2024 marked a transformative period in the realm of peptide science, underscored by it's economic impacts, substantial investments, and a shifting landscape in healthcare delivery. Key highlights of this dynamic month include:
1. Orbis Medicines' breakthrough with €26M funding for new oral peptide therapies.
2. The projection by Goldman Sachs of GLP-1 drugs as key drivers of economic growth.
3. WuXi AppTec navigating the complexities of US-China biopharma tensions.
4. Novo Nordisk's strides in sustainable peptide synthesis through green chemistry.
5. CordenPharma's expansion enhancing peptide manufacturing for clinical development.
6. Computational advancements in cyclic peptide design for Keap1 inhibition.
7. Novel synthetic peptides targeting disease-related nucleic acids.
8. The fusion of machine learning and DFT for creating antioxidant peptides.
9. The development of innovative, temperature-sensitive fibrils for drug delivery.
10. Curve Therapeutics' securing of £40.5M from Pfizer, spotlighting peptide drug discovery.
Get the summary here [https://lnkd.in/g53UNxAQ] and dive deeper into each of these pioneering stories.
Herbalist and Educator.
2moInterested